Market closedNon-fractional
Sight Sciences/SGHT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Sight Sciences
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Ticker
SGHT
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Menlo Park, United States
Employees
214
Website
www.sightsciences.com
Sight Sciences Metrics
BasicAdvanced
$400M
Market cap
-
P/E ratio
-$1.12
EPS
2.74
Beta
-
Dividend rate
Price and volume
Market cap
$400M
Beta
2.74
Financial strength
Current ratio
13.007
Quick ratio
12.223
Long term debt to equity
30.856
Total debt to equity
30.856
Interest coverage (TTM)
-9.90%
Management effectiveness
Return on assets (TTM)
-19.32%
Return on equity (TTM)
-42.84%
Valuation
Price to revenue (TTM)
4.818
Price to book
3.63
Price to tangible book (TTM)
3.63
Price to free cash flow (TTM)
-9.727
Growth
Revenue change (TTM)
8.27%
Earnings per share change (TTM)
-32.78%
3-year revenue growth (CAGR)
39.88%
3-year earnings per share growth (CAGR)
-34.74%
What the Analysts think about Sight Sciences
Analyst Ratings
Majority rating from 6 analysts.
Sight Sciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$19M
2.67%
Net income
-$16M
52.83%
Profit margin
-84.37%
48.85%
Sight Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.30
-$0.27
-$0.22
-$0.33
-
Expected
-$0.34
-$0.32
-$0.32
-$0.28
-$0.30
Surprise
-12.13%
-15.05%
-30.60%
19.71%
-
Sight Sciences News
AllArticlesVideos
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
GlobeNewsWire·1 week ago
Sight Sciences Announces the Release of its First Sustainability Report
GlobeNewsWire·2 months ago
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sight Sciences stock?
Sight Sciences (SGHT) has a market cap of $400M as of July 27, 2024.
What is the P/E ratio for Sight Sciences stock?
The price to earnings (P/E) ratio for Sight Sciences (SGHT) stock is 0 as of July 27, 2024.
Does Sight Sciences stock pay dividends?
No, Sight Sciences (SGHT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Sight Sciences dividend payment date?
Sight Sciences (SGHT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sight Sciences?
Sight Sciences (SGHT) has a beta rating of 2.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Sight Sciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.